APA (7th ed.) Citation

HJ, K., JE, S., A, K., SY, P., J, K., JY, L., . . . DW, K. (2025). KF1601, a dual inhibitor of BCR: :ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia. Molecular cancer, 24(1), 114. https://doi.org/10.1186/s12943-025-02292-z

Chicago Style (17th ed.) Citation

HJ, Kwon, et al. "KF1601, a Dual Inhibitor of BCR: :ABL1 and FLT3, Overcomes Drug Resistance in FLT3+ Blast Phase Chronic Myeloid Leukemia." Molecular Cancer 24, no. 1 (2025): 114. https://doi.org/10.1186/s12943-025-02292-z.

MLA (9th ed.) Citation

HJ, Kwon, et al. "KF1601, a Dual Inhibitor of BCR: :ABL1 and FLT3, Overcomes Drug Resistance in FLT3+ Blast Phase Chronic Myeloid Leukemia." Molecular Cancer, vol. 24, no. 1, 2025, p. 114, https://doi.org/10.1186/s12943-025-02292-z.